×
For best experience we recommend to activate Javascript in your browser.
EIF2S1 antibody (AA 1-239)
This Rabbit Polyclonal antibody specifically detects EIF2S1 in WB, IHC and ELISA. It exhibits reactivity toward Human.
Quick Overview for EIF2S1 antibody (AA 1-239) (ABIN7569194)
Target
See all EIF2S1 Antibodies
EIF2S1
(Eukaryotic Translation Initiation Factor 2 Subunit 1 (EIF2S1))
Reactivity
All reactivities for EIF2S1 antibodies
Human
Host
All hosts for EIF2S1 antibodies
Rabbit
Clonality
All clonalities for EIF2S1 antibodies
Polyclonal
Conjugate
All conjugates for EIF2S1 antibodies
This EIF2S1 antibody is un-conjugated
Application
All applications for EIF2S1 antibodies
Western Blotting (WB), Immunohistochemistry (IHC), ELISA
Product Details anti-EIF2S1 Antibody
(hide)
Binding Specificity
All epitopes for EIF2S1 antibodies
AA 1-239
Purpose
Anti-Human EIF2S1 Polyclonal Antibody
Purification
Antigen affinity purification.
Immunogen
E. coli - derived recombinant Human EIF2S1 (Met1-Thr239).
Isotype
IgG
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Buffer
0.01M PBS, pH 7.4, 50 % glycerol, 0.05 % Proclin 300.
Preservative
ProClin
Precaution of Use
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C,-80 °C
Storage Comment
Use a manual defrost freezer and avoid repeated freeze thaw cycles.Store at 4°C for frequent use.Store at -20 to -80 °C for twelve months from the date of receipt.
Target Details for EIF2S1
(hide)
Target
EIF2S1
(Eukaryotic Translation Initiation Factor 2 Subunit 1 (EIF2S1))
Alternative Name
EIF2S1
Background
EIF2A, eIF-2A, Eukaryotic translation initiation factor 2 subunit alpha, Eukaryotic translation initiation factor 2 subunit 1, EIF2S1, eIF-2-alpha, eIF-2alpha
UniProt
P05198
Pathways
Ribonucleoprotein Complex Subunit Organization , ER-Nucleus Signaling , Hepatitis C
Recently viewed
(hide)
Chat with us , powered by LiveChat